

- Iwasaka T, Imaizumi T. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells: a pilot study and a randomized controlled trial. *Lancet*. 2002;360:427–435.
12. Olin JW. Thromboangiitis obliterans (Buerger's disease). *N Engl J Med*. 2000;343:864–869.
 13. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). *Circulation*. 1990;82(5 Suppl):IV3–IV8.
 14. Matsushita M, Shionoya S, Matsumoto T. Urinary cotinine measurement in patients with Buerger's diseases: effects of active and passive smoking on the disease process. *J Vasc Surg*. 1991;14:53–58.
 15. Szuba A, Cooke JP. Thromboangiitis obliterans: an update on Buerger's disease. *West J Med*. 1998;168:225–260.
 16. Mills JL, Taylor LMJ, Porter JM. Buerger's disease in the modern era. *Am J Surg*. 1987;154:123–129.
 17. Silvestre J-S, Gojova A, Brun V, Potteaux S, Esposito B, Duriez M, Clergue M, Le Ricousse-Roussanne S, Barateau V, Merval R, Groux H, Tobelem G, Levy B, Tedgui A, Mallat Z. Transplantation of bone marrow-derived mononuclear cells in ischemic apolipoprotein E-knockout mice accelerates atherosclerosis without altering plaque composition. *Circulation*. 2003;108:2839–2842.
 18. George J, Afek A, Abashidze A, Shmilovich H, Deutsch V, Kopolovich J, Miller H, Keren G. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. *Arterioscler Thromb Vasc Biol*. 2005;25:2636–2641.
 19. Wakitani S, Takaoka K, Hattori T, Miyazawa N, Iwanaga T, Takeda S, Watanabe TK, Tanigami A. Embryonic stem cells injected into the mouse knee joint form teratomas and subsequently destroy the joint. *Rheumatology (Oxford)*. 2003;42:162–165.
 20. Yoon Y, Park J, Tkebuchava T, Luedeman C, Losordo D. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. *Circulation*. 2004;109:3154–3157.

CLINICAL PERSPECTIVE

The favorable short-term outcome of bone marrow mononuclear cell transplantation (BM-MNC) transplantation has been established in patients with critical limb ischemia. However, the long-term outcome of this treatment strategy has not been determined yet. In our case series, we documented that long-term adverse events, including death and unfavorable angiogenesis, were observed in 4 of 8 patients receiving BM-MNC transplantation. The first patient suffered sudden death at 20 months after transplantation at 30 years of age. The second patient with incomplete healing of a skin ulcer showed worsening of the lesion at 4 months. The third patient had worsening of rest pain at 8 months. The last patient developed an arteriovenous shunt in the foot at 7 months, which spontaneously regressed by 1 year. Given the current incomplete knowledge on the safety and efficacy of this strategy, it is suggested that careful long-term monitoring is required in patients receiving BM-MNC transplantation. To our knowledge, this is the first report on the long-term outcome of transplantation of BM-MNCs for critical limb ischemia, and the first that documents the development of unfavorable angiogenesis and sudden death after therapeutic angiogenesis.

Original article

Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis

Shunsuke Ohnishi^{a,*}, Bobby Yanagawa^{a,1}, Koichi Tanaka^a, Yoshinori Miyahara^a, Hiroaki Obata^{a,b}, Masaharu Kataoka^a, Makoto Kodama^b, Hatsue Ishibashi-Ueda^c, Kenji Kangawa^d, Soichiro Kitamura^e, Noritoshi Nagaya^{a,*}

^a Department of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute, Fujishirodai 5-7-1, Osaka 565-8565, Japan

^b Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

^c Department of Pathology, National Cardiovascular Center, Osaka, Japan

^d Department of Biochemistry, National Cardiovascular Center Research Institute, Osaka, Japan

^e Department of Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan

Received 11 May 2006; received in revised form 29 August 2006; accepted 2 October 2006

Available online 13 November 2006

Abstract

Acute myocarditis is a non-ischemic inflammatory disease of the myocardium for which there is currently no specific treatment. We have previously shown that mesenchymal stem cells (MSC) can ameliorate heart injury during acute ischemia and in dilated cardiomyopathy; however, the therapeutic potential in acute myocarditis is unclear. In this study, we investigated the ability of MSC to attenuate myocardial injury and dysfunction during the acute phase of experimental myocarditis. Ten-week-old male Lewis rats were injected with porcine myosin to induce myocarditis. Cultured MSC (3×10^6 cells/rat) were injected intravenously 7 days after myosin injection. At 3 weeks, myosin injection resulted in severe inflammation and significant deterioration of cardiac function. MSC transplantation attenuated increases in CD68-positive inflammatory cells and monocyte chemoattractant protein-1 (MCP-1) expression in myocardium, and improved cardiac function in this model. Furthermore, myocardial capillary density was higher in myocarditis tissue, and was further increased by MSC transplantation. *In vitro*, cultured adult rat cardiomyocytes were injured in response to MCP-1, whereas this effect was attenuated by MSC-derived conditioned medium, suggesting cardioprotective effects of MSC acting in a paracrine manner. MSC transplantation attenuated myocardial injury and dysfunction in a rat model of acute myocarditis, at least in part through paracrine effects of MSC. © 2006 Elsevier Inc. All rights reserved.

Keywords: Acute myocarditis; Mesenchymal stem cell; Paracrine effect; Cytokine; Cell death

1. Introduction

Acute myocarditis is a non-ischemic heart disease characterized by myocardial inflammation and edema. This disease is associated with rapidly progressive heart failure, arrhythmias and sudden death [1,2]. Although the early evidence for efficacy of immunoglobulin and interferon therapy appears promising, these results have yet to be demonstrated in randomized or controlled clinical trials. The current options are restricted to supportive care for heart failure or arrhythmias. The lack of

specific treatment and the potential severity of the illness emphasize the importance of novel and effective therapeutic strategies for myocarditis.

Mesenchymal stem cells (MSC) are multipotent stem cells present in adult tissues, and have the ability to differentiate into a variety of lineages, including vascular smooth muscle cells, endothelial cells and cardiomyocytes [3,4]. We have previously reported that bone marrow-derived MSC engrafted in experimental myocardial infarction expressed both cardiac and endothelial phenotypes in the heart, and further increased capillary density and decreased the infarct size [5]. Moreover, we have recently demonstrated that monolayered MSC derived from adipose tissue reversed wall thinning in the scar area and improved cardiac function in rats with myocardial infarction [6]. The cardioprotective effects of MSC are known to be mediated

* Corresponding authors. Tel.: +81 6 6833 5012; fax: +81 6 6833 9865.

E-mail addresses: sonsihi@ri.ncvc.go.jp (S. Ohnishi),

nnagaya@ri.ncvc.go.jp (N. Nagaya).

¹ Drs Ohnishi and Yanagawa contributed equally to this study.

not only by their differentiation into vascular cells and cardiomyocytes, but also by their ability to supply large amounts of angiogenic, anti-apoptotic and mitogenic factors [5–7]. These findings suggest the therapeutic potential of MSC for heart failure. However, whether intravenously transplanted MSC attenuate myocardial inflammation and cardiac dysfunction in acute myocarditis remains unknown.

In the present study, we used porcine myosin-induced acute myocarditis in Lewis rats. This model closely resembles human giant cell myocarditis, a frequently fatal disorder characterized by multinucleated giant cells in the myocardium [8]. To examine the therapeutic potential of MSC in the acute phase of myocarditis, MSC were intravenously injected into rats 7 days after myosin injection.

Thus, the purposes of this study were 1) to investigate whether intravenous transplantation of MSC improves cardiac function and pathological findings including myocardial inflammation in rats with myosin-induced myocarditis, and 2) to investigate the underlying mechanisms responsible for the effects of MSC.

2. Materials and methods

2.1. Animals

Ten-week-old male Lewis rats (Japan SLC, Hamamatsu, Japan) were used in all experiments, and were maintained in our animal facilities. The experimental protocols were approved by The Animal Care Committee of the National Cardiovascular Center.

2.2. Preparation of cardiac myosin

Purified cardiac myosin from the ventricular muscle of pig hearts was prepared according to a procedure described previously [8]. The antigen was dissolved at a concentration of 20 mg/ml in phosphate-buffered saline (PBS) containing 0.3 M KCl, mixed with an equal volume of complete Freund's adjuvant containing 11 mg/ml *Mycobacterium tuberculosis* (Difco Laboratories, Sparks, MD, USA). Rats were anesthetized with an intraperitoneal injection of 20 mg/kg sodium pentobarbital, and 0.1 ml of the antigen-adjuvant emulsion was injected into the each footpad.

2.3. Acute myocarditis model

Forty-five rats were randomly divided into three groups and received the following treatment: 1) 0.2 ml saline and sham surgery (Sham group, $n=15$), 2) 0.2 ml cardiac myosin antigen and sham surgery (MyoC group, $n=15$), and 3) 0.2 ml cardiac myosin followed by MSC transplantation 7 days post-myosin injection (MyoC+MSC group, $n=15$). Rats were weighed and observed daily for signs of morbidity and for death.

2.4. Preparation and transplantation of bone marrow-derived MSC

MSC were prepared as described previously [5]. Briefly, bone marrow cells were isolated by flushing out the femoral

and tibial cavities with PBS, and plated onto 10-cm dishes in complete culture medium: Dulbecco's Modified Eagle's Medium (DMEM), 15% fetal bovine serum, 100 U/ml penicillin and 100 μ g/ml streptomycin. Five days after plating, non-adherent cells were removed, and adherent cells were further propagated for 4 to 5 passages.

Seven days after myosin injection, MSC (3×10^6 cells) or vehicle (0.9% saline) was intravenously administered via the jugular vein. Sham rats also received saline administration but without myosin injection.

2.5. Hemodynamic studies

Hemodynamic studies were performed on day 21 post-myosin injection. Anesthesia was maintained with an intraperitoneal injection of 20 mg/kg sodium pentobarbital, and a 1.5 Fr micromanometer-tipped catheter was placed in the left ventricle through the right carotid artery (Millar Instruments, Houston, TX, USA). Heart rate (HR) was also monitored by electrocardiography. HR, mean arterial pressure (MAP), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), maximum dP/dt (Max dP/dt) and minimum dP/dt (Min dP/dt) were used as indices of hemodynamics, and recorded simultaneously during ventilation after a minimum equilibration period of 20 min.

2.6. Echocardiographic studies

Echocardiography was performed on day 21 post-myosin injection. Rats were anesthetized with an intraperitoneal injection of 20 mg/kg sodium pentobarbital. A 12 MHz probe was placed at the left 4th intercostal space for M-mode imaging using 2D echocardiography (Sonos 5500, Philips, Bothell, WA, USA). Left ventricular systolic dimension (LVDs), left ventricular diastolic dimension (LVDd), anterior wall thickness (AWT), posterior wall thickness (PWT) and ejection fraction (EF) were measured, and taken as an average of three beats. Fractional shortening (%FS) was calculated as $(LVDd - LVDs) / LVDd \times 100$.

2.7. Histological examination

The heart was excised above the origin of the great vessels, and heart weight and body weight were recorded on day 21 post-myosin injection. Portions of the midventricular heart, spleen, pancreas, kidney and liver were fixed with 4% paraformaldehyde, embedded in paraffin, sectioned at 4- μ m thickness, stained with either hematoxylin and eosin (H & E) or Masson's trichrome, and subjected to immunohistochemical staining. H & E-stained sections were evaluated by a cardiovascular pathologist (H.I.-U.) for the characterization of myocardial injury and inflammation without knowledge of the experimental groups, on the following scale: 0, absent or questionable presence; 1, limited focal distribution; 2–3, intermediate severity; and 4, coalescent and extensive foci throughout the entire transversely sectioned ventricular tissue.

2.8. Immunohistochemical study

Paraffin-embedded heart sections were washed in increasing concentrations of ethanol and then with PBS. Sections were incubated with Protein Block (DakoCytomation, Glostrup, Denmark), then with mouse anti-rat von Willebrand Factor (vWF) (DakoCytomation), CD68 (DakoCytomation) or monocyte chemoattractant protein-1 (MCP-1) (BD Biosciences Pharmingen, San Jose, CA, USA) antibody in diluent for 40 min, followed by incubation with horseradish peroxidase (HRP)-linked rabbit anti-mouse IgG (DakoCytomation) for 30 min. Sections were visualized using 0.5% diaminobenzidine and 0.03% hydrogen peroxide, and counterstained with hematoxylin. The numbers of CD68-stained cells and vWF-stained capillaries were determined in 10 randomly selected fields ($\times 200$).

2.9. Enzyme-linked immunosorbent assay (ELISA)

Serum MCP-1 level of rats on day 21 post-myosin injection was measured using a Rat MCP-1 ELISA kit (Biosource International, Carmarillo, CA, USA). Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) levels in the supernatant of MSC culture (2.3×10^5 cells in 10-cm dish cultured for 48 h) were measured using ELISA kits, according to the manufacturers' protocols (HGF, Institute of Immunology, Tokyo, Japan; VEGF, R&D Systems, Minneapolis, MN, USA).

2.10. Isolation of cardiomyocytes

Ventricular cardiomyocytes were obtained as described previously with modification [9]. Briefly, after heparinization by intraperitoneal injection of 1000 U/kg heparin sodium, the heart was rapidly excised, and pulmonary, connective and other noncardiac tissues were removed. The heart was then mounted on the cannula of a modified Langendorff apparatus and perfused with buffer containing 0.75 mg/ml collagenase type I (Worthington, Lakewood, NJ, USA), 0.5 mg/ml hyaluronidase (Sigma) and 1% bovine serum albumin (fraction V, ICN, Aurora, OH, USA), in a recirculating fashion for 3 h. After the perfusion sequence, the heart was removed from the perfusion apparatus, the atrium was removed, and gently minced. The enzyme-containing buffer was harvested and the cardiomyocytes resuspended in fresh buffer. The calcium concentration in the suspension was raised stepwise to 1.2 mM. Quiescent, calcium-tolerant cardiomyocytes were gravitationally separated from any nonventricular cells and resuspended in complete culture medium. The culture medium was exchanged for fresh medium to remove the damaged myocytes that failed to attach 3 h after plating. After this procedure, 80% to 90% myocytes were viable and showed rod-shape.

2.11. Cardiomyocyte stimulation and MTS assay

To assess cardioprotective effects of MSC acting in a paracrine manner, we investigated whether conditioned

medium obtained from MSC culture attenuated MCP-1-induced cardiomyocyte injury. Cardiomyocytes were plated on 96-well plates (1×10^3 viable cells/well) precoated with laminin (BD Biosciences Pharmingen). After 3 h, the medium was changed to fresh DMEM containing 15% FBS or conditioned medium obtained from MSC culture, with or without 50 ng/ml MCP-1 (R&D Systems, Minneapolis, MN, USA). After 24 h, the cellular level of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), indicative of the mitochondrial function in living cells and cell viability, was measured ($n=6$) with a CellTiter96 Aqueous One Kit (Promega, Madison, WI, USA) and a Microplate Reader (490 nm, Bio-Rad, Hercules, CA, USA).

2.12. In vitro apoptosis assay

Terminal dUTP nick end labeling (TUNEL) assay (ApopTag Fluorescein In Situ Apoptosis Detection Kit, Chemicon International, Temecula, CA, USA) was performed to evaluate apoptosis of cultured cardiomyocytes. After incubation for 24 h, cardiomyocytes were fixed in 1% paraformaldehyde, and TUNEL staining was performed for detection of apoptotic nuclei according to the manufacturer's




Fig. 1. Effects of MSC transplantation on hemodynamic parameters in acute myocarditis. (A) Left ventricular end-diastolic pressure (LVEDP) and (B) maximum dP/dt (Max dP/dt) were measured in sham-operated rats given vehicle (Sham group), myosin-treated rats given vehicle (MyoC group), and myosin-treated rats given MSC (MyoC+MSC group). Values are mean \pm S.E. * $P < 0.05$ vs Sham, † $P < 0.05$ vs MyoC group.

Table 1
Physiological parameters in three experimental groups

	Sham	MyoC	MyoC+MSC
HW/BW (g/kg)	2.9±0.3	6.4±0.3*	4.7±0.3* [†]
HR (bpm)	446±11	363±14*	442±12* [†]
MAP (mm Hg)	108±3	87±3*	108±4 [†]
LVSP (mm Hg)	130±2	105±4*	125±4 [†]
Min dP/dt (mm Hg/s)	-5440±199	-3097±183*	-4617±171* [†]

Sham, sham-operated rats given vehicle; MyoC, myosin-treated rats given vehicle; MyoC+MSC, myosin-treated rats given MSC (3×10^6 cells); HW/BW, heart weight to body weight ratio; HR, heart rate; MAP, mean arterial pressure; LVSP, left ventricular systolic pressure; Min dP/dt, minimum dP/dt. Data are mean±S.E. * $P < 0.05$ vs Sham, [†] $P < 0.05$ vs MyoC group.

instructions. The cells were then mounted in medium containing DAPI. Randomly selected microscopic fields ($n=5$) were evaluated to calculate the ratio of TUNEL-positive cells to total cells.

Table 2
Echocardiographic findings in three experimental groups

	Sham	MyoC	MyoC+MSC
LVDs (mm)	3.1±0.1	5.0±0.4*	3.8±0.2 [†]
EF (%)	74.9±1.2	56.6±3.4*	71.2±3.5 [†]
AWT diastole (mm)	1.9±0.1	3.0±0.2*	3.0±0.3*
PWT diastole (mm)	1.9±0.1	3.4±0.1*	2.7±0.2* [†]

Sham, sham-operated rats given vehicle; MyoC, myosin-treated rats given vehicle; MyoC+MSC, myosin-treated rats given MSC (3×10^6 cells); LVDs, left ventricular systolic dimension; EF, ejection fraction; AWT, anterior wall thickness; PWT, posterior wall thickness. Data are mean±S.E. * $P < 0.05$ vs Sham, [†] $P < 0.05$ vs MyoC group.

2.13. Creatine kinase (CK) activity assay

CK activity in culture media was measured after incubation of cardiomyocytes for 24 h ($n=5$), using the enzyme measurement kit (Kanto Chemical, Tokyo, Japan).




Fig. 2. Effects of MSC transplantation on echocardiographic parameters in acute myocarditis. (A) Representative echocardiographic images showing wall thickening and poor movement in the MyoC group, and improvement of cardiac contractility in the MyoC+MSC group. (B and C) MSC transplantation significantly improved fractional shortening (%FS) and left ventricular diastolic dimension (LVDd). Values are mean±S.E. * $P < 0.05$ vs Sham, [†] $P < 0.05$ vs MyoC group.

2.14. Statistical analysis

Data were expressed as mean \pm standard error (S.E.). Comparisons of parameters among groups were made by one-way ANOVA, followed by Newman–Keuls' test. Differences were considered significant at $P < 0.05$.

3. Results

3.1. Improvement in cardiac function by MSC transplantation

Two of 15 rats in the MyoC group died on day 19 and day 21 post-myosin injection, respectively, whereas the MyoC+MSC group had no mortality. At 3 weeks post-myosin injection, the MyoC group showed increased heart weight/body weight ratio (HW/BW) and LVEDP, and decreased MAP and Max dP/dt compared with the Sham group, indicating the presence of acute heart failure in this model (Fig. 1 and Table 1). These parameters subsequently returned to baseline with MSC

transplantation (MyoC+MSC group). On echocardiography, the MyoC group showed an increase in LVDs and LVDd, and a significant reduction in %FS and EF (Fig. 2 and Table 2). MSC transplantation significantly improved these parameters (MyoC+MSC group).

3.2. Attenuation of myocardial inflammation by MSC transplantation

Myocardial necrosis and tissue granulation as well as giant cell infiltration and edema were markedly increased in our model of acute myocarditis (Fig. 3A). MSC transplantation significantly attenuated these changes observed in the MyoC group. MSC-transplanted hearts exhibited a consistent tendency for a reduction of tissue granulation, inflammation and edema, on blinded histological grading by a cardiovascular pathologist (H.I.U.), as compared to the MyoC group (Fig. 3B). Hearts showed limited fibrosis in the MyoC group, and this observation was not significantly attenuated by MSC




Fig. 3. Effects of MSC transplantation on pathological changes in acute myocarditis. (A) Representative myocardial sections show markedly decreased inflammation and tissue necrosis (H & E) and a comparable degree of early fibrosis (Masson's trichrome) after MSC transplantation (MyoC+MSC) as compared to control (MyoC, arrows). Insets are transverse sections of myocardium. Scale bars: 50 μ m. (B) Semi-quantitative histological grades for necrosis and tissue granulation as well as for infiltration of giant cells and edema were significantly lower after MSC transplantation (MyoC+MSC) compared to control (MyoC). Sham tissues exhibited no measurable pathological change. Values are mean \pm S.E. * $P < 0.05$ vs Sham, † $P < 0.05$ vs MyoC group.

transplantation, possibly because of the acute nature of this experiment (Fig. 3B).

Notably, marked histiocytic infiltration was demonstrated by CD68-positive cells, including multinucleated giant cells, in myocarditis (MyoC group), and this was significantly attenuated by MSC transplantation (Figs. 4A and B). In myocarditis, there was an increase in MCP-1 expression localized to the vascular endothelium and also in cardiomyocytes surrounding areas of inflammation (Fig. 5A). The hearts in the MyoC+MSC group showed a partial decrease in MCP-1 expression. Serum MCP-1 level was greatly increased in the MyoC group, whereas the increase was significantly attenuated in the MyoC+MSC group (Fig. 5B).

3.3. Effect of MSC on angiogenesis

To investigate the angiogenic effect of MSC transplantation in the myocardium, immunohistochemical analysis of vWF was performed. Capillary density was increased in the MyoC group (Figs. 6A and B). Notably, in MSC-transplanted tissues, capillary density was increased compared to that in the MyoC group. The clustering of relatively small vessels seen in MSC-transplanted hearts was indicative of recent neovascularization.

3.4. Cardioprotective effects of MSC in paracrine manner

Because MSC transplantation had anti-inflammatory and tissue-protective effects and induced angiogenesis, some

paracrine effects were expected. To confirm the paracrine effects of MSC *in vitro*, cardiomyocytes were isolated from adult rats, and cultured with MCP-1 in the standard medium or in the conditioned medium obtained from MSC culture. The standard medium containing MCP-1 resulted in a decrease in viable cardiomyocytes; however, MSC-derived conditioned medium containing MCP-1 attenuated the decrease in viable cardiomyocytes (Fig. 7A). TUNEL staining showed that the standard medium containing MCP-1 markedly induced apoptosis of cardiomyocytes (Figs. 7B and C). However, the conditioned medium of MSC significantly attenuated MCP-1-induced cardiomyocyte apoptosis. In addition, CK activity in standard medium containing MCP-1 was significantly increased, whereas the conditioned medium markedly attenuated the CK activity induced by MCP-1 (Fig. 7D).

To investigate whether MSC secreted angiogenic and anti-fibrotic factors, VEGF and HGF levels in MSC culture were measured by ELISA assay. MSC secreted large amounts of VEGF and HGF compared to standard medium, respectively (Fig. 7E).

4. Discussion

In this study, we focused on the therapeutic potential of MSC transplantation in the acute phase of myocarditis. We showed that 1) MSC transplantation 1 week after myosin injection improved cardiac function and attenuated pathological findings including myocardial inflammation, and that 2)




Fig. 4. Effects of MSC transplantation on myocardial CD68 expression in acute myocarditis. (A) Representative myocardial sections immunohistochemically stained for CD68 demonstrate a marked decrease in CD68-positive cells, including giant cells, after MSC transplantation (MyoC+MSC) as compared to control (MyoC). Scale bars: 100 μ m. (B) Semi-quantitative counts of CD68-positive cells demonstrate a significant reduction in the MyoC+MSC group. Values are mean \pm S.E. * P <0.05 vs Sham, $\dagger P$ <0.05 vs MyoC group.




Fig. 5. Effects of MSC transplantation on myocardial MCP-1 expression and serum MCP-1 level. (A) Representative MCP-1-stained myocardial sections from MyoC and MyoC+MSC groups. Scale bars: 50 μ m. (B) Serum level of MCP-1 measured by ELISA. Values are mean \pm S.E. * P <0.05 vs Sham, † P <0.05 vs MyoC group.




Fig. 6. Effects of MSC on neovascularization. (A) Representative myocardial sections immunohistochemically stained for vWF showing increased microvasculature (arrows) in control hearts (MyoC), which was more marked after MSC transplantation (MyoC+MSC). Scale bars: 50 μ m. (B) Capillary density measured in 10 random representative high-power fields showing a significant increase in control (MyoC) and a further increase after MSC transplantation (MyoC+MSC) over the Sham group. Values are mean \pm S.E. * P <0.05 vs Sham, † P <0.05 vs MyoC group.

MSC had cardioprotective effects acting in a paracrine manner.

The rat model of myosin-induced experimental myocarditis provides a model that resembles human giant cell myocarditis [8,10]. Although the majority of acute myocarditis is linked to a viral infection such as coxsackievirus B3, this viral infection can in some cases cause an autoimmune myocarditis with chronic

myocardial inflammation without viral persistence, due to the exposure of cardiac autoantigens to the immune system [11,12]. This myocarditis model is triphasic, consisting of an antigen priming phase from days 0–14, an autoimmune response phase from days 14–21, and a reparative phase thereafter, associated chronically with a dilated cardiomyopathy phenotype [13]. In our previous study, MSC were transplanted at the reparative




Fig. 7. Effects of MSC on MCP-1-induced cardiomyocyte injury *in vitro*. (A) MTS assay after 24 h of culture with or without MCP-1 in standard medium vs MSC conditioned medium. * $P < 0.05$ vs control in standard medium, † $P < 0.05$ vs MCP-1 in conditioned medium. (B) Quantitative analysis of TUNEL staining after 24 h of culture with or without MCP-1 in standard medium vs MSC conditioned medium. * $P < 0.05$ vs control in standard medium, † $P < 0.05$ vs MCP-1 in standard medium. (C) Representative TUNEL staining show increased apoptotic cardiomyocytes (green) cultured with MCP-1 in standard medium, which was attenuated by MSC conditioned medium. Nuclei were counterstained with DAPI (blue). Scale bars: 50 μ m. (D) CK activity after 24 h of culture with or without MCP-1 in standard medium vs MSC conditioned medium. * $P < 0.05$ vs control in standard medium, † $P < 0.05$ vs MCP-1 in standard medium. (E) ELISA for VEGF and HGF secreted from cultured MSC as compared to standard medium. † $P < 0.05$ vs standard medium.

phase with a dilated cardiomyopathy phenotype, by direct injection into the myocardium [7]. In the present study, however, MSC were transplanted 1 week following myosin injection, corresponding to the acute phase of myocarditis, by intravenous injection, because this model is more relevant to clinical situations. Myosin injection caused acute heart failure as indicated by increased LVEDP and decreased Max dP/dt and %FS, and 2 out of 15 rats died; however, intravenous injection of MSC in the acute phase significantly improved the heart failure as determined by improvement of these parameters, and no death was observed.

Wang et al. have shown that embryonic stem (ES) cells transplanted into a mouse model of myocarditis regenerate cardiomyocytes, decrease inflammation and increase survival, possibly through migration of ES cells and differentiation into cardiomyocytes [14]. In the present study, we examined the therapeutic potential of transplanted MSC, which are more applicable to clinical situations than ES cells, in a rat model of acute myocarditis. Recent studies have demonstrated that autologous or allogeneic MSC strongly suppress T-lymphocyte proliferation [15,16]. These findings raise the possibility that MSC have the ability to attenuate inflammatory responses. Interestingly, the present study demonstrated that transplantation of MSC attenuated the infiltration of CD68-positive inflammatory cells and the expression of MCP-1 in a rat model of acute myocarditis. MCP-1 is a member of the C–C subfamily of chemokines with chemoattractant activity for major inflammatory cells, and is known to play an important role in the induction of experimental acute myocarditis [17,18]. Cardiac-targeted expression of MCP-1 results in monocyte/macrophage infiltration into the heart, and causes interstitial fibrosis and ventricular chamber dilation [19]. In the myosin-induced acute myocarditis model, MCP-1 expression is increased in the heart from days 15–27 post-myosin injection, and serum MCP-1 level is elevated from days 15–24 [18]. In consistent with this report, our model showed an increase in MCP-1 in the heart and serum on day 21 post-myosin injection, and MSC transplantation attenuated the increase in MCP-1 and the infiltration of CD68-positive inflammatory cells. Furthermore, earlier studies have shown that MSC express CCR2, the receptor for MCP-1, and that MCP-1 promotes the migration of MSC that express CCR2 [20,21]. Thus, it is speculated that MSC secrete some anti-inflammatory factors in response to MCP-1; however, the precise mechanisms for the anti-inflammatory effect still remains to be elucidated.

Because MCP-1 plays an important role in this myosin-induced myocarditis model, we examined the direct effect of MCP-1, besides its chemoattractant activity, on adult rat cardiomyocytes. Our *in vitro* experiment demonstrated that MCP-1 stimulation on cardiomyocytes resulted in an increase of cell injury and death, whereas MSC-derived conditioned medium attenuated these effects. It has been reported that CCR2 expression is increased in the failing myocardium, and MCP-1 stimulation on cardiomyocytes induces other inflammatory cytokines such as IL-1 β and IL-6, which may reduce cardiomyocyte contractility partly via induction of apoptosis

[22–25]. In addition, our previous and present study demonstrated that cultured MSC secreted large amounts of angiogenic and anti-apoptotic factors such as VEGF, HGF, insulin-like growth factor-1 and adrenomedullin [7]. Furthermore, a recent study demonstrated that conditioned medium obtained from MSC culture had cardioprotective effect [26]. Taken together, although various factors might be involved, MSC might have cardioprotective effects in a paracrine manner in response to MCP-1.

In the present study, MSC transplantation increased capillary density in the myocardium. Improvement in myocardial vascular supply has been shown to decrease necrosis and inflammation in viral myocarditis [8,27,28]. We have previously reported increased capillary density associated with improved cardiac function and decreased infarct size following MSC transplantation in a rat model of myocardial infarction [5]. These results suggest that MSC-induced neovascularization may have contributed to the improvement of cardiac function in this rat model of acute myocarditis. However, when PKH26 dye-labeled MSC were intravenously injected in rats with acute myocarditis, only a small fraction of PKH26-labeled cells were positive for troponin T 2 weeks after transplantation (data not shown). Our previous study demonstrated that ~3% of the intravenously administered MSCs were incorporated into the heart 24 h after transplantation in rats with acute myocardial infarction [5]. Although the animal model and the evaluation time were different, our present study showed that only a small number of administered MSC was differentiated into endothelial cells or cardiomyocytes, thus the contribution of the differentiated MSC to the improvement of cardiac function in this model appears to be rather insignificant.

In conclusion, MSC transplantation attenuated myocardial injury and dysfunction in a rat model of acute myocarditis, at least in part through paracrine effects of MSC.

Acknowledgments

This work was funded by a post-doctoral fellowship from the Japan Society for the Promotion of Science, and research grants for Cardiovascular Disease (16C-6, 17C-1 and 18C-1) and Human Genome Tissue Engineering 009 from the Ministry of Health, Labor and Welfare.

References

- [1] Levi D, Alejos J. Diagnosis and treatment of pediatric viral myocarditis. *Curr Opin Cardiol* 2001;16:77–83.
- [2] Feldman AM, McNamara D. Myocarditis. *N Engl J Med* 2000;343:1388–98.
- [3] Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143–7.
- [4] Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. *Cytotherapy* 2005;7:36–45.
- [5] Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M, et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. *Am J Physiol: Heart Circ Physiol* 2004;287:H2670–6.

- [6] Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. *Nat Med* 2006;12:459–65.
- [7] Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. *Circulation* 2005;112:1128–35.
- [8] Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. *Clin Immunol Immunopathol* 1990;57:250–62.
- [9] Tanaka K, Honda M, Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. *J Am Coll Cardiol* 2001;37:676–85.
- [10] Kodama M, Matsumoto Y, Fujiwara M, Zhang SS, Hanawa H, Itoh E, et al. Characteristics of giant cells and factors related to the formation of giant cells in myocarditis. *Circ Res* 1991;69:1042–50.
- [11] Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. From infection to autoimmunity. *J Autoimmun* 2001;16:175–86.
- [12] Cunningham MW. T cell mimicry in inflammatory heart disease. *Mol Immunol* 2004;40:1121–7.
- [13] Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. *Circ Res* 1994;75:278–84.
- [14] Wang JF, Yang Y, Wang G, Min J, Sullivan MF, Ping P, et al. Embryonic stem cells attenuate viral myocarditis in murine model. *Cell Transplant* 2002;11:753–8.
- [15] Di Nicola M, Carlo-Stella C, Magni M, Milanese M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood* 2002;99:3838–43.
- [16] Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. *Transplantation* 2003;75:389–97.
- [17] Rollins BJ. Chemokines. *Blood* 1997;90:909–28.
- [18] Fuse K, Kodama M, Hanawa H, Okura Y, Ito M, Shiono T, et al. Enhanced expression and production of monocyte chemoattractant protein-1 in myocarditis. *Clin Exp Immunol* 2001;124:346–52.
- [19] Kolattukudy PE, Quach T, Bergese S, Breckenridge S, Hensley J, Altschuld R, et al. Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. *Am J Pathol* 1998;152:101–11.
- [20] Ji JF, He BP, Dheen ST, Tay SS. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. *Stem Cells* 2004;22:415–27.
- [21] Wang L, Li Y, Chen J, Gautam SC, Zhang Z, Lu M, et al. Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. *Exp Hematol* 2002;30:831–6.
- [22] Damas JK, Eiken HG, Oie E, Bjerkeli V, Yndestad A, Ueland T, et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. *Cardiovasc Res* 2000;47:778–87.
- [23] Damas JK, Aukrust P, Ueland T, Odegaard A, Eiken HG, Gullestad L, et al. Monocyte chemoattractant protein-1 enhances and interleukin-10 suppresses the production of inflammatory cytokines in adult rat cardiomyocytes. *Basic Res Cardiol* 2001;96:345–52.
- [24] Ing DJ, Zang J, Dzau VJ, Webster KA, Bishopric NH. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. *Circ Res* 1999;84:21–33.
- [25] Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross Jr J, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. *Cell* 1999;97: 189–98.
- [26] Gneccchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. *Nat Med* 2005;11:367–8.
- [27] Lee JK, Zaidi SH, Liu P, Dawood F, Cheah AY, Wen WH, et al. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. *Nat Med* 1998;4:1383–91.
- [28] Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis: acute effects of bosentan, an endothelin receptor antagonist. *Circulation* 1999;100:1823–9.



Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats

Yoshinori Miyahara^a, Shunsuke Ohnishi^a, Hiroaki Obata^a, Kozo Ishino^b, Shunji Sano^b, Hidezo Mori^c, Kenji Kangawa^d, Soichiro Kitamura^e, Noritoshi Nagaya^{a,*}

^a Department of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute, Osaka, Japan

^b Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

^c Department of Cardiac Physiology, National Cardiovascular Center Research Institute, Osaka, Japan

^d Department of Biochemistry, National Cardiovascular Center Research Institute, Osaka, Japan

^e Department of Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan

Received 13 August 2006

Available online 7 September 2006

Abstract

Beraprost sodium, an orally active prostacyclin analogue, has vasoprotective effects such as vasodilation and antiplatelet activities. We investigated the therapeutic potential of beraprost for myocardial ischemia. Immediately after coronary ligation of Sprague–Dawley rats, beraprost (200 µg/kg/day) or saline was subcutaneously administered for 28 days. Four weeks after coronary ligation, administration of beraprost increased capillary density in ischemic myocardium, decreased infarct size, and improved cardiac function in rats with myocardial infarction. Beraprost markedly increased the number of CD34-positive cells and c-kit-positive cells in plasma. Also, four weeks after coronary ligation of chimeric rats with GFP-expressing bone marrow, bone marrow-derived cells were incorporated into the infarcted region and its border zone. Treatment with beraprost increased the number of GFP/von Willebrand factor-double-positive cells in the ischemic myocardium. These results suggest that beraprost has beneficial effects on ischemic myocardium partly by its ability to enhance neovascularization in ischemic myocardium by mobilizing bone marrow cells.

© 2006 Elsevier Inc. All rights reserved.

Keywords: Prostacyclin analogue; Myocardial infarction; Neovascularization; Bone marrow mobilization

Interruption of myocardial blood flow leads to rapid death of cardiomyocytes and vascular structures, resulting in the development of heart failure [1]. Stem or progenitor cells are mobilized from bone marrow into the peripheral blood in response to tissue ischemia, migrate to sites of injured tissues, and differentiate into endothelial cells and cardiomyocytes [2–4]. However, the compensatory mechanisms are insufficient to heal infarcted myocardium. Earlier studies have shown that bone marrow cells artificially mobilized by cytokines repair the infarcted heart and improve cardiac function after acute myocardial infarction [5,6]. Therefore, enhancement of bone marrow cell mobili-

zation leading to neovascularization following revascularization would be beneficial for the treatment of acute myocardial infarction.

Beraprost sodium (BPS) is a chemically stable prostacyclin analogue owing to its cyclo-pentabenzofuranyl structure [7]. It has been well established that BPS has vasoprotective effects such as vasodilation and antiplatelet activities [8–11]. Thus, BPS has been used in the treatment of peripheral arterial disease [12,13] and pulmonary arterial hypertension [14,15]. Although a limited number of studies suggest therapeutic potential of prostacyclin for the treatment of myocardial ischemia [16–18], the underlying mechanisms still remain unclear. In addition, little information is available regarding the therapeutic potential of prostacyclin analogues such as BPS for myocardial ischemia. A recent study has shown that BPS activates endothelial

* Corresponding author. Fax: +81 6 6833 9865.

E-mail address: nnagaya@ri.ncvc.go.jp (N. Nagaya).

nitric oxide synthase (eNOS) through the c-AMP/protein kinase A pathway [19]. Activation of eNOS is known to contribute to bone marrow cell mobilization, leading to neovascularization [20]. These results raise the possibility that BPS may have beneficial effects on the ischemic myocardium through enhancement of bone marrow cell mobilization.

Thus, the purposes of this study were: (1) to examine the effect of BPS on mobilization and recruitment of bone marrow cells after acute myocardial infarction, (2) to investigate whether BPS induces neovascularization in the ischemic myocardium, and (3) to investigate whether treatment with BPS improves cardiac function in rats with myocardial infarction.

Methods

Model of myocardial infarction. We used male Sprague–Dawley rats (Japan SLC Inc., Hamamatsu, Japan) weighing 185–215 g. Myocardial infarction was produced by left coronary ligation, as described previously [21]. Briefly, after rats were anesthetized with sodium pentobarbital (30 mg/kg), they were artificially ventilated with a volume-regulated respirator. The heart was exposed via a left thoracotomy incision. Then, the left coronary artery was ligated 2–3 mm from its origin between the pulmonary artery conus and the left atrium with a 6-0 Prolene suture. Finally, the heart was restored to its normal position, and the chest was closed. Experimental protocols were performed in accordance with the “Guidelines of the Animal Care Ethics Committee of the National Cardiovascular Center Research Institute”, which complies NIH Guidelines.

Administration of BPS. Immediately after coronary ligation, BPS (200 µg/kg/day, Astellas Pharma Inc., Tokyo, Japan) was subcutaneously administered to surviving rats using an osmotic mini-pump for 4 weeks (BPS group, $n = 12$). As a control, saline was similarly administered to rats receiving coronary ligation (Control group, $n = 12$).

Echocardiographic studies. Echocardiographic studies were performed 4 weeks after coronary ligation. M-mode tracings were obtained at the level of the papillary muscles using an echocardiographic system equipped with a 7.5-MHz phased-array transducer (HP SONOS 5500; Hewlett Packard Co., Andover, MA). Anterior and posterior end-diastolic and end-systolic wall thickness, LV end-diastolic and end-systolic dimensions, and LV fractional shortening were measured by the American Society for Echocardiography leading-edge method in three consecutive cardiac cycles. LV meridional wall stress was estimated as $0.344 \times \text{LV pressure} \times \{ \text{LV dimension} / (1 + \text{PWT} / \text{LV dimension}) \}$, where PWT is posterior wall thickness [22].

Hemodynamic studies. Hemodynamic studies were performed 4 weeks after coronary ligation, following echocardiography. After anesthesia with pentobarbital sodium, a 1.5F micromanometer-tipped catheter (Millar Instruments Inc., Houston, TX) was advanced into the LV through the right common carotid artery. Hemodynamic variables were measured with a pressure transducer connected to a polygraph. After completion of these measurements, the left and right ventricles and the lungs were excised and weighed. Infarct size was determined as a percentage of the entire LV area ($n = 5$ in each group), as reported previously [23]. Briefly, incisions were made in the posterior LV so that the tissue could be pressed flat. The circumference of the entire flat LV and of the visualized infarcted area, as judged from both the epicardial and endocardial sides, was outlined on a clear plastic sheet. The difference in weight between the two marked areas on the sheet was used to determine infarct size and was expressed as a percentage of LV surface area.

Measurement of plasma ANP level. Blood samples were obtained 4 weeks after coronary ligation. Plasma atrial natriuretic peptide (ANP), a marker for heart failure, was measured by enzyme immunoassay (Peninsula Laboratories Inc., San Carlos, CA).

Mononuclear cell mobilization and FACS analysis. To investigate whether administration of BPS mobilizes bone marrow cells, an additional 12 rats were randomized to receive BPS (200 µg/kg/day, BPS group, $n = 6$) or saline (Control group, $n = 6$). On the third day of BPS or saline treatment, 4 ml of blood was drawn from the inferior vena cava of each rat. Peripheral blood was obtained at the end of infusion. After mononuclear cells were counted, they were incubated for 30 min at 4 °C with fluorescein isothiocyanate (FITC)-conjugated mouse monoclonal antibodies against rat CD34 (clone ICO-115, Santa Cruz) and CD45 (clone OX-1), and FITC-conjugated rabbit anti-rat c-Kit polyclonal antibody (clone C-19, Santa Cruz). Immunofluorescence-labeled cells were analyzed by quantitative flow cytometry with a FACSCalibur flow cytometer (BD Biosciences, Mountain View, CA). Isotype-identical antibodies served as controls.

RT-PCR assay. To investigate whether bone marrow cells express the prostacyclin receptor (IP receptor), we analyzed expression of its mRNA by reverse transcription-polymerase chain reaction (RT-PCR). In brief, total RNA of bone marrow cells was extracted with guanidine isothiocyanate (RNeasy Mini Kit, Qiagen). Then, reverse-transcribed single-stranded cDNA was subjected to PCR (PCR Amplification Kit, Takara) using primer sets for the IP receptor (Hokkaido System Science Co., Ltd., Sapporo, Japan, forward, 5'-GGCAGGAGAGGATGAAGTTTACC-3'; reverse, 5'-GTCAGAGGCACAGCAGTCAATGG-3') and G3PDH (Clontech Laboratories Inc., Mountain View, CA, forward, 5'-TG AAGTTCGGTGTCAACGGATTGGC-3'; reverse, 5'-CATGTAGG CCATGAGGTCCACCAC-3').

Creation of bone marrow-chimeric rats. To assess recruitment of bone marrow cells after BPS administration, bone marrow transplantation was performed by using male normal Sprague–Dawley rats as recipients and male Green fluorescent protein (GFP)-transgenic rats (SD-Tg [Act-EGFP] CZ-004Os, Japan SLC Inc.) as donors, using a previously described method [24]. Briefly, bone marrow was harvested by flushing the cavity of femurs and tibias from GFP-transgenic rats with phosphate-buffered saline. Then, 3×10^7 GFP-positive bone marrow cells were individually administered to 12 lethally irradiated (900c Gray) rats via the tail vein. Four weeks after transplantation, flowcytometric analysis determined that 90% of peripheral blood mononuclear cells from both donors and 8 of 12 chimeric rats were GFP-positive, suggesting the establishment of stable chimerism. These chimeric rats were subjected to left coronary ligation, followed by administration of BPS (200 µg/kg/day, BPS group, $n = 4$) or saline (Control group, $n = 4$) using an osmotic mini-pump for 4 weeks.

Histological examination. To detect fibrosis in the cardiac muscle, the LV myocardium ($n = 5$, each group) was fixed in 10% formalin, cut transversely in three sections, embedded in paraffin, and stained with Masson's trichrome. To detect capillary endothelial cells in the peri-infarct area, we performed DAB staining (LSAB2 System HRP, Dako Cytomation Co., Denmark) using rabbit polyclonal anti-von Willebrand factor (vWF) antibody (Dako). A total of 10 different fields from three different sections were randomly selected, and the number of capillaries was counted in the peri-infarct area using a light microscope at 200× magnification. Capillary density was expressed as the mean number of capillaries per square millimeter. Also, 4 weeks after coronary ligation in bone marrow-chimeric rats ($n = 4$ in each group), the LV myocardium was excised, embedded in OCT compound, snap-frozen in liquid nitrogen, and cut transversely into 6-µm-thick sections from base to apex. Immunofluorescent staining was performed using rabbit polyclonal anti-vWF antibody (Dako), mouse monoclonal anti-cardiac troponin T antibody (Neomarkers, Fremont, CA), and rabbit polyclonal Alexa 488-conjugated anti-GFP antibody (Molecular Probes Inc., Eugene, OR). The nuclei were counterstained with 4',6'-diamidino-2-phenylindole (DAPI). We measured the number of GFP/vWF-double-positive cells incorporated into vascular structures in 10 randomly selected fields in the peri-infarct area per section in a blinded fashion using a fluorescence microscope.

Statistical analysis. Numerical values are expressed as means \pm SEM. Comparisons of parameters between two groups were made by unpaired Student's *t* test. A value of $p < 0.05$ was considered significant.

Results

Cardiac structure

Body weight at 4 weeks after coronary ligation was significantly greater in the BPS group than in the Control group (Table 1). Right ventricular weight and lung weight in the BPS group were significantly smaller than those in the Control group, although LV weight did not differ between the two groups. Moderate to large infarcts were

Table 1
Physiological profiles of experimental groups

	Control	BPS
Number	12	12
Body weight (g)		
Baseline	198 ± 3	204 ± 3
After treatment	319 ± 6	352 ± 9*
LV wt/body wt (g/kg)	2.28 ± 0.04	2.27 ± 0.04
RV wt/body wt (g/kg)	0.99 ± 0.05	0.61 ± 0.02**
Lung wt/body wt (g/kg)	6.55 ± 0.62	3.88 ± 0.1**
Plasma AND level (pg/ml)	798 ± 99	498 ± 57*

Control, infarct rats without treatment; BPS, infarct rats treated with BPS administration; AND, atrial natriuretic protein. Data are expressed as means ± SEM. * $p < 0.05$, ** $p < 0.01$ vs. Control group.

observed in the Control group (Fig. 1A). However, administration of BPS significantly decreased infarct size in rats with myocardial infarction (Fig. 1A and B). BPS significantly decreased LV end-diastolic dimension (LVDD) (Fig. 1C).

Cardiac function

Neither heart rate nor mean arterial pressure differed between the BPS and Control groups (Table 2). LV fractional shortening and LV maximum dP/dt in the BPS group were significantly greater than those in the Control group (Fig. 2A and B). LV end-diastolic pressure (LVEDP) in the BPS group was significantly lower than that in the Control group (Fig. 2C). LV minimum dP/dt was also improved by BPS (Fig. 2D). Treatment with BPS attenuated the increase in plasma ANP level after myocardial infarction (Table 1). BPS significantly increased anterior wall thickening, although it did not significantly alter posterior wall thickening (Table 2). Thickness of the anterior and posterior walls tended to be greater in the BPS group, but these changes did not reach statistical significance. LV diastolic wall stress in the BPS group was significantly lower than that in the Control group.




Fig. 1. (A) Representative examples of Masson's trichrome staining of transverse sections of LV myocardium 4 weeks after coronary ligation. Scale bars = 2 mm. (B,C) Quantitative analysis of infarct size and LV end-diastolic dimension (LVDD). Infarcted area and LVDD in the BPS group were significantly smaller than those in the Control group. Data are expressed as means ± SEM. * $p < 0.05$, ** $p < 0.01$ vs. Control group.

Table 2
Echocardiographic and hemodynamic data

	Control	BPS
AWT diastole (mm)	0.62 ± 0.04	0.74 ± 0.05
AW thickening (%)	17 ± 3	34 ± 6*
PWT diastole (mm)	1.55 ± 0.07	1.70 ± 0.04
PW thickening (%)	43 ± 4	49 ± 3
Heart rate (bpm)	458 ± 7	471 ± 10
Mean arterial pressure (mmHg)	103 ± 5	115 ± 4
LV systolic pressure (mmHg)	113 ± 4	127 ± 5*
LV diastolic wall stress (kdyne/cm ²)	24 ± 4	5 ± 1**
LV systolic wall stress (kdyne/cm ²)	267 ± 18	225 ± 14

AWT, anterior wall thickness; AW, anterior wall; PWT, posterior wall thickness; PW, posterior wall. Data are expressed as means ± SEM. **p* < 0.05, ***p* < 0.01 vs. Control group.

Mobilization of bone marrow cells

RT-PCR demonstrated that IP receptor mRNA was expressed in bone marrow cells (Fig. 3A), indicating a direct effect of BPS on these cells. Three-day administration of BPS significantly increased the number of peripheral blood mononuclear cells compared to saline administration (Fig. 3B). Administration of BPS markedly increased the number of circulating progenitor cells such as CD34-positive cells and c-kit-positive cells (Fig. 3C and D). BPS also increased the number of CD45-positive hematopoietic lineage cells (Fig. 3E).

BPS-induced neovascularization

Chimeric rats with GFP-expressing bone marrow were used to assess recruitment of bone marrow cells. Four weeks after coronary ligation, bone marrow-derived GFP-positive cells were incorporated predominantly into the infarcted region and its border zone (Fig. 4A), while these cells were rarely detected in the noninfarcted myocardium. Some of the GFP-positive cells stained for vWF and formed vascular structures. Semi-quantitative analysis demonstrated that the number of GFP-positive cells in the myocardium was significantly greater in the BPS group

than in the Control group (Fig. 4B). The number of GFP-vWF double-positive cells (bone marrow-derived endothelial cells) in the ischemic myocardium was significantly greater in the BPS group than in the Control group (Fig. 4C). In addition, a small number of GFP-troponin T-double-positive cells were observed in the BPS group (Fig. 4D).

Capillary density

In the peri-infarct area, clustering of relatively small vessels was seen in BPS-treated hearts, which is indicative of recent endothelial regeneration (Fig. 5A). Semi-quantitative analysis also demonstrated that administration of BPS significantly increased the capillary density in the peri-infarct area compared to the Control group (Fig. 5B).

Discussion

In the present study, we demonstrated that treatment with BPS (1) decreased infarct size and improved cardiac structure and function in rats with acute myocardial infarction, (2) increased the number of circulating progenitor cells such as CD34-positive cells and c-kit-positive cells in rats, and (3) increased the number of bone marrow-derived endothelial cells and the capillary density in the ischemic myocardium. These results suggest that BPS may have beneficial effects on ischemic myocardium at least in part through enhancement of neovascularization by mobilizing bone marrow cells.

Earlier studies have reported that prostacyclin has cardioprotective effects in ischemia–reperfusion injury through inhibition of neutrophil activation and migration [25,26]. BPS is also reported to inhibit chemotaxis and superoxide anion production of neutrophils which contribute to tissue damage by releasing tissue destructive lysosomal enzymes [27]. Infusion of BPS has been shown to reduce infarct size in the dog heart with left coronary occlusion by reducing myocardial oxygen demand and by inhibition of the migration of neutrophils [28]. However, these




Fig. 2. Cardioprotective effects of BPS on echocardiographic and hemodynamic parameters. FS, fractional shortening; LVEDP, LV end-diastolic pressure; Max and Min dP/dt, maximum and minimum dP/dt. Data are expressed as means ± SEM. **p* < 0.05, ***p* < 0.01 vs. Control group.




Fig. 3. BPS-induced mobilization of bone marrow cells. (A) Expression of prostacyclin receptor (IP receptor) on bone marrow cells. (B–E) Quantification of BPS-induced MNC mobilization by FACS analysis. Administration of BPS markedly increased the number of circulating progenitor cells such as CD34-positive cells and c-kit-positive cells. BPS also increased the number of CD45-positive hematopoietic lineage cells. Data are expressed as means \pm SEM. * $p < 0.05$, ** $p < 0.01$ vs. Control group.

biological activities of BPS appear to be insufficient to explain the decrease in infarct size as well as suppression of LV remodeling.

Recent studies have shown that mobilization of bone marrow cells by cytokines promotes myocardial repair and regeneration after acute myocardial infarction [5,6]. In the present study, three-day administration of BPS markedly increased the number of circulating progenitor cells such as CD34-positive cells and c-kit-positive cells in rats. In addition, treatment with BPS enhanced recruitment of bone marrow cells to the ischemic myocardium and increased capillary density in the peri-infarct area. Earlier studies have shown that CD34-positive cells have angiogenic potential to treat ischemic heart [29–31]. Also, another stem cell fraction, c-kit-positive cells have ability to repair ischemic myocardium by differentiating into vascular endothelial cells [32,33]. These findings suggest that administered BPS induces neovascularization partly via enhancement of bone marrow cell mobilization. RT-PCR demonstrated that IP receptor mRNA was expressed in bone marrow cells, indicating a direct effect of BPS on these cells. A recent study has shown that BPS increases eNOS expression in cultured endothelial cells through activation of c-AMP/Protein kinase A signal transduction [19]. Also, earlier studies have shown that eNOS plays essential role in the recruitment of EPCs to the ischemic myocardium [20]. Taken together, administered BPS may act as a

potent stimulator of cell mobilization from bone marrow, although further studies are necessary to examine the underlying mechanisms.

In the present study, treatment with BPS significantly attenuated infarct size after myocardial infarction. BPS improved cardiac function and attenuated the development of LV remodeling after acute myocardial infarction, as indicated by increases in LV fractional shortening and maximum dP/dt , and decreases in LVEDP and LVDD. Taken together, BPS may attenuate myocardial infarction through enhancement of neovascularization via modification of bone marrow kinetics. Interestingly, a small fraction of mobilized bone marrow cells expressed cardiac troponin T in the ischemic myocardium in the BPS group, suggesting that BPS may partially contribute to myocardial regeneration after acute myocardial infarction. Earlier studies have demonstrated that BPS has other beneficial effects for ischemic heart disease including anti-thrombotic activity [34], inhibition of reperfusion injury [35], and prevention of coronary spasm [36], and re-stenosis [37]. These findings suggest that administration of BPS may be a promising therapy for acute myocardial infarction.

Granulocyte colony stimulating factor (G-CSF) is currently used agent for mobilization of bone marrow. Infusion of G-CSF after myocardial infarction improves LV function increasing peripheral stem cell fraction [5,38]. A recent clinical trial, however, claimed the G-CSF therapy




Fig. 4. BPS-induced neovascularization. (A) Representative immunofluorescent images stained with antibodies to von-Willbrand factor (vWF, red) and green fluorescent protein (GFP, green). Nuclei were counterstained with DAPI (blue). (B,C) Semi-quantitative analyses of numbers of GFP-positive cells and GFP-vWF double-positive cells in the peri-infarct area. (D) Representative immunofluorescent image of GFP-positive cells (green) expressing cardiac troponin T (red) observed in the BPS group. Scale bars = 50 μ m. Data are expressed as means \pm SEM. ** $p < 0.01$ vs. Control group.

has serious problem with re-stenosis after recanalization [39]. On the other hand, the safety of BPS has been identified in the treatment of peripheral arterial disease [12,13] and pulmonary arterial hypertension [14,15]. A randomized, controlled clinical trial failed to demonstrate therapeutic potential of prostacyclin for the treatment of severe congestive heart failure [40], which has long discouraged the pursuit of prostacyclin as a therapeutic option for the treatment of acute myocardial infarction. Interestingly, however, double-blinded, randomized, placebo-controlled, large-scale studies showed that treatment with BPS decreased vascular events in patients with peripheral

arterial disease [41,42]. Thus, adequate use of BPS for only acute myocardial infarction may have beneficial effects on ischemic myocardium, although further preclinical trials are required to verify the safety and efficacy of BPS.

Conclusion

In summary, administration of BPS improved cardiac structure and function in rats with acute myocardial infarction. This beneficial effect of BPS may be mediated partly by its ability to enhance neovascularization in ischemic myocardium by mobilizing bone marrow cells.




Fig. 5. (A) Representative samples stained with antibody to von Willebrand factor by bright-field DAB. (B) Quantitative analysis of capillary density in peri-infarct area. Administration of BPS increased capillary density by 37%. Scale bars = 50 μ m. Data are expressed as means \pm SEM. ** $p < 0.01$ vs. Control group.

Acknowledgment

This work was supported by research grants for Cardiovascular Disease (16C-6) from the Ministry of Health, Labor and Welfare, and for Japan Vascular Disease Research Foundation.

References

- [1] A. Saraste, K. Pulkki, M. Kallajoki, K. Henriksen, M. Parvinen, L.M. Voipio-Pulkki, Apoptosis in human acute myocardial infarction, *Circulation* 95 (1997) 320–323.
- [2] S. Shintani, T. Murohara, H. Ikeda, T. Ueno, T. Honma, A. Katoh, K. Sasaki, T. Shimada, Y. Oike, T. Imaizumi, Mobilization of endothelial progenitor cells in patients with acute myocardial infarction, *Circulation* 103 (2001) 2776–2779.
- [3] D. Orlic, J. Kajstura, S. Chimenti, I. Jakoniuk, S.M. Anderson, B. Li, J. Pickel, R. McKay, B. Nadal-Ginard, D.M. Bodine, A. Leri, P. Anversa, Bone marrow cells regenerate infarcted myocardium, *Nature* 410 (2001) 701–705.
- [4] H. Oh, S.B. Bradfute, T.D. Gallardo, T. Nakamura, V. Gaussin, Y. Mishina, J. Pocius, L.H. Michael, R.R. Behringer, D.J. Garry, M.L. Entman, M.D. Schneider, Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction, *Proc. Natl. Acad. Sci. USA* 100 (2003) 12313–12318.
- [5] D. Orlic, J. Kajstura, S. Chimenti, F. Limana, I. Jakoniuk, F. Quaini, B. Nadal-Ginard, D.M. Bodine, A. Leri, P. Anversa, Mobilized bone marrow cells repair the infarcted heart, improving function and survival, *Proc. Natl. Acad. Sci. USA* 98 (2001) 10344–10349.
- [6] T. Asahara, T. Takahashi, H. Masuda, C. Kalka, D. Chen, H. Iwaguro, Y. Inai, M. Silver, J.M. Isner, VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells, *EMBO J.* 18 (1999) 3964–3972.
- [7] T. Murata, T. Murai, T. Kanai, Y. Ogaki, K. Sanai, H. Kanda, S. Sato, N. Kajikawa, T. Umetsu, H. Matsuura, General pharmacology of beraprost sodium, *Arzneimittelforschung* 39 (1989) 867–876.
- [8] T. Akiba, M. Miyazaki, N. Toda, Vasodilator actions of TRK-100, a new prostaglandin I₂ analogue, *Br. J. Pharmacol.* 89 (1986) 703–711.
- [9] S. Nishio, H. Matsuura, N. Kanai, Y. Fukatsu, T. Hirano, N. Nishikawa, K. Kameoka, T. Umetsu, The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species, *Jpn J. Pharmacol.* 47 (1988) 1–10.
- [10] J.L. Demolis, A. Robert, M. Mouren, C. Funck-Brentano, P. Jaillon, Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers, *J. Cardiovasc. Pharmacol.* 22 (1993) 711–716.
- [11] P. Nony, P. Ffrench, P. Girard, S. Delair, S. Azoulay, J.P. Girre, M. Dechavanne, J.P. Boissel, Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects, *Can. J. Physiol. Pharmacol.* 74 (1996) 887–893.
- [12] M. Murakami, M. Watanabe, H. Furukawa, H. Nakahara, The prostacyclin analogue beraprost sodium prevents occlusion of bypass grafts in patients with lower extremity arterial occlusive disease: a 20-year retrospective study, *Ann. Vasc. Surg.* 19 (2005) 838–842.
- [13] L.T. Cooper, Beraprost for the treatment of intermittent claudication, *J. Am. Coll. Cardiol.* 41 (2003) 1679–1686.
- [14] Y. Okano, T. Yoshioka, A. Shimouchi, T. Satoh, T. Kunieda, Orally active prostacyclin analogue in primary pulmonary hypertension, *Lancet* 349 (1997) 1365.

- [15] N. Nagaya, M. Uematsu, Y. Okano, T. Satoh, S. Kyotani, F. Sakamaki, N. Nakanishi, K. Miyatake, T. Kunieda, Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension, *J. Am. Coll. Cardiol.* 34 (1999) 1188–1192.
- [16] A.M. Lefer, M.L. Ogletree, J.B. Smith, M.J. Silver, K.C. Nicolaou, W.E. Barnette, G.P. Gasic, Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia, *Science* 200 (1978) 52–54.
- [17] B.I. Jugdutt, G.M. Hutchins, B.H. Bulkley, L.C. Becker, Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs, *Circ. Res.* 49 (1981) 685–700.
- [18] J.A. Melin, L.C. Becker, Salvage of ischemic myocardium by prostacyclin during experimental myocardial infarction, *J. Am. Coll. Cardiol.* 2 (1983) 279–286.
- [19] K. Niwano, M. Arai, K. Tomaru, T. Uchiyama, Y. Ohyama, M. Kurabayashi, Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI₂ signal and NO pathways, *Circ. Res.* 93 (2003) 523–530.
- [20] A. Aicher, C. Heeschen, C. Mildner-Rihm, C. Urbich, C. Ihling, K. Technau-Ihling, A.M. Zeiher, S. Dimmeler, Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells, *Nat. Med.* 9 (2003) 1370–1376.
- [21] T. Nishikimi, K. Uchino, E.D. Frohlich, Effects of α 1-adrenergic blockade on intrarenal hemodynamics in heart failure rats, *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 262 (1998) R198–R203.
- [22] P.S. Douglas, N. Reichel, T. Plappert, A. Muhammad, M.G. St John Sutton, Comparison of echocardiographic methods for assessment of left ventricular shortening and wall stress, *J. Am. Coll. Cardiol.* 9 (1987) 945–951.
- [23] Y.W. Chien, R.W. Barbee, A.A. Macphee, E.D. Frohlich, N.C. Trippondo, Increased ANF secretion after volume expansion is preserved in rats with heart failure, *Am. J. Physiol.* 254 (1988) R185–R191.
- [24] T. Ito, A. Suzuki, E. Imai, M. Okabe, M. Hori, Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling, *J. Am. Soc. Nephrol.* 12 (2001) 2625–2635.
- [25] P.J. Simpson, R.F. Todd 3rd, J.C. Fantone, J.K. Mickelson, J.D. Griffin, B.R. Lucchesi, Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion, *J. Clin. Invest.* 81 (1988) 624–629.
- [26] W.W. Nichols, J. Mehta, T.J. Wargovich, D. Franzini, D. Lawson, Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist, *Angiology* 40 (1989) 209–221.
- [27] M. Kainoh, R. Imai, T. Nakadake, M. Hattori, S. Nishio, Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes, *Biochem. Pharmacol.* 39 (1990) 477–483.
- [28] Y. Ueno, Y. Miyauchi, S. Nishio, Beraprost sodium protects occlusion/reperfusion injury in the dog by inhibition of neutrophil migration, *Gen. Pharmacol.* 25 (1994) 427–432.
- [29] A. Kawamoto, T. Tkebuchava, J. Yamaguchi, H. Nishimura, Y.S. Yoon, C. Milliken, S. Uchida, O. Masuo, H. Iwaguro, H. Ma, A. Hanley, M. Silver, M. Learney, D.W. Losordo, J.M. Isner, T. Asahara, Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia, *Circulation* 107 (2003) 461–468.
- [30] A. Kawamoto, T. Asahara, D.W. Losordo, Transplantation of endothelial progenitor cells for therapeutic neovascularization, *Cardiovasc. Radiat. Med.* 3 (2002) 221–225.
- [31] A. Weber, I. Pedrosa, A. Kawamoto, N. Himes, J. Munasinghe, T. Asahara, N.M. Rofsky, D.W. Losordo, Magnetic resonance mapping of transplanted endothelial progenitor cells for therapeutic neovascularization in ischemic heart disease, *Eur. J. Cardiothorac. Surg.* 26 (2004) 137–143.
- [32] J. Kajstura, M. Rota, B. Whang, S. Cascapera, T. Hosoda, C. Bearzi, D. Nurzynska, H. Kasahara, E. Zias, M. Bonafe, B. Nadal-Ginard, D. Torella, A. Nascimbene, F. Quaini, K. Urbanek, A. Leri, P. Anversa, Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion, *Circ. Res.* 96 (2005) 127–137.
- [33] R. Lanza, M.A. Moore, T. Wakayama, A.C. Perry, J.H. Shieh, J. Hendriks, A. Leri, S. Chimenti, A. Monsen, D. Nurzynska, M.D. West, J. Kajstura, P. Anversa, Regeneration of the infarcted heart with stem cells derived by nuclear transplantation, *Circ. Res.* 94 (2004) 820–827.
- [34] Y. Uchida, T. Hanai, K. Hasegawa, K. Kawamura, T. Oshima, Recanalization of obstructed coronary artery by intracoronary administration of prostacyclin in patients with acute myocardial infarction, *Adv. Prostaglandin Thromboxane Leukot. Res.* 11 (1983) 377–383.
- [35] C.Y. Xiao, A. Hara, Yuhki K., T. Fujino, H. Ma, Y. Okada, O. Takahata, T. Yamada, T. Murata, S. Narumiya, F. Ushikubi, Roles of prostaglandin I₂ and thromboxane A₂ in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors, *Circulation* 104 (2001) 2210–2215.
- [36] A. Szczeklik, J. Szczeklik, R. Nizankowski, P. Glusko, Prostacyclin for unstable angina, *N. Engl. J. Med.* 303 (1980) 881.
- [37] M.L. Knudtson, V.F. Flintoft, D.L. Roth, J.L. Hansen, H.J. Duff, Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty, *J. Am. Coll. Cardiol.* 15 (1990) 691–697.
- [38] F. Kuethe, H.R. Figulla, M. Herzau, M. Voth, M. Fritzenwanger, T. Opfermann, K. Pachmann, A. Krack, H.G. Sayer, D. Gottschild, G.S. Werner, Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction, *Am. Heart J.* 150 (2005) 115.
- [39] H.J. Kang, H.S. Kim, S.Y. Zhang, K.W. Park, H.J. Cho, B.K. Koo, Y.J. Kim, D. Soo Lee, D.W. Sohn, K.S. Han, B.H. Oh, M.M. Lee, Y.B. Park, Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial, *Lancet* 363 (2004) 751–756.
- [40] R.M. Califf, K.F. Adams, W.J. McKenna, M. Gheorghide, B.F. Uretsky, S.E. McNulty, H. Darius, K. Schulman, F. Zannad, E. Handberg-Thurmond, F.E. Harrell Jr., W. Wheeler, J. Soler-Soler, K. Swedberg, A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST), *Am. Heart J.* 134 (1997) 44–54.
- [41] M. Lievre, S. Morand, B. Besse, J.N. Fiessinger, J.P. Boissel, Oral beraprost sodium, a prostaglandin I₂ analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group, *Circulation* 102 (2000) 426–431.
- [42] E.R. Mohler 3rd, W.R. Hiatt, J.W. Olin, M. Wade, R. Jeffs, A.T. Hirsch, Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I₂ analogue: a double-blinded, randomized, controlled trial, *J. Am. Coll. Cardiol.* 41 (2003) 1679–1686.

Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction

Yoshinori Miyahara^{1,9}, Noritoshi Nagaya^{1,9}, Masaharu Kataoka¹, Bobby Yanagawa¹, Koichi Tanaka¹, Hiroyuki Hao², Kozo Ishino³, Hideyuki Ishida⁴, Tatsuya Shimizu⁵, Kenji Kangawa⁶, Shunji Sano³, Teruo Okano⁵, Soichiro Kitamura⁷ & Hidezo Mori⁸

Mesenchymal stem cells are multipotent cells that can differentiate into cardiomyocytes and vascular endothelial cells. Here we show, using cell sheet technology, that monolayered mesenchymal stem cells have multipotent and self-propagating properties after transplantation into infarcted rat hearts. We cultured adipose tissue-derived mesenchymal stem cells characterized by flow cytometry using temperature-responsive culture dishes. Four weeks after coronary ligation, we transplanted the monolayered mesenchymal stem cells onto the scarred myocardium. After transplantation, the engrafted sheet gradually grew to form a thick stratum that included newly formed vessels, undifferentiated cells and few cardiomyocytes. The mesenchymal stem cell sheet also acted through paracrine pathways to trigger angiogenesis. Unlike a fibroblast cell sheet, the monolayered mesenchymal stem cells reversed wall thinning in the scar area and improved cardiac function in rats with myocardial infarction. Thus, transplantation of monolayered mesenchymal stem cells may be a new therapeutic strategy for cardiac tissue regeneration.

Myocardial infarction, a main cause of heart failure, leads to loss of cardiac tissue and impairment of left ventricular function. Therefore, restoring the scarred myocardium is desirable for the treatment of heart failure. Although needle injections of bone marrow cells into the myocardium have been performed for cardiac regeneration^{1–5}, it is difficult to reconstruct sufficient cardiac mass in the thinned scar area after myocardial infarction.

Recently, our colleagues have developed cell sheets using temperature-responsive culture dishes⁶. These cell sheets allow for cell-to-cell connections and maintain the presence of adhesion proteins because enzymatic digestion is not needed^{7–10}. Therefore, cell sheet transplantation may be a promising strategy for partial cardiac tissue reconstruction. Skeletal myoblasts, fetal cardiomyocytes and embryonic stem cells have been considered as candidates for an implantable cell

source^{11–13}. It is difficult, however, to produce a multilayered construct requiring a vascular network. Thus, autologous somatic stem cells with self-propagating properties that can induce angiogenesis are a desirable cell source for a transplantable sheet.

Mesenchymal stem cells (MSCs) are multipotent adult stem cells that reside within the bone marrow microenvironment^{14,15}. MSCs can differentiate not only into osteoblasts, chondrocytes, neurons and skeletal muscle cells, but also into vascular endothelial cells¹⁶ and cardiomyocytes^{17–20}. In contrast to their hematopoietic counterparts, MSCs are adherent and can expand in culture. Recently, MSCs have been isolated from adipose tissue^{21–24}, which is typically abundant in individuals with cardiovascular disease. Here, we investigated the therapeutic potency of monolayered MSCs derived from adipose tissue using cell sheet technology.

RESULTS

Characteristics of adipose tissue-derived MSCs

We isolated MSCs from subcutaneous adipose tissue of male Sprague-Dawley rats on the basis of the adherent properties of these cells. We obtained $1.7 \times 10^5 \pm 0.2 \times 10^5$ cells from 1 g adipose tissue in a 12-h culture. By day 4 of culture of the minced adipose tissue, spindle-shaped adherent cells were apparent and formed symmetric colonies. After approximately three to four passages, most adherent cells expressed CD29 and CD90 (**Supplementary Fig. 1** online). In contrast, the majority of adherent cells were negative for CD34 and CD45. They were also negative for CD31, a marker for vascular endothelial cells, and negative for α smooth muscle actin (α SMA), a marker for smooth muscle cells. A small fraction of adherent cells expressed CD71, CD106 and CD117. These results were similar to those from bone marrow-derived MSCs^{15,22,25} (**Supplementary Fig. 1** online). Using previously described methods^{16,22,26}, we confirmed that these adipose-derived adherent cells, like bone marrow-derived MSCs, were multipotent, as judged by their ability to differentiate into adipocytes, osteoblasts and vascular endothelial cells. Thus, we

¹Department of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute and ²Department of Pathology, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka, 565-8565, Japan. ³Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8555, Japan. ⁴Department of Physiology, School of Medicine, Tokai University, Bohseidai, Isehara, Kanagawa, 259-1193, Japan. ⁵Institute of Advanced Biomedical Engineering and Science, Tokyo Woman's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. ⁶Department of Biochemistry, National Cardiovascular Center Research Institute and ⁷Department of Cardiovascular Surgery, National Cardiovascular Center and ⁸Department of Cardiac Physiology, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka, 565-8565, Japan. ⁹These authors contributed equally to this work. Correspondence should be addressed to N.N. (nnagaya@ri.ncvc.go.jp) or H.M. (hidemori@ri.ncvc.go.jp).

Received 9 August 2005; accepted 3 March 2006; published online 2 April 2006; doi:10.1038/nm1391